AVITA Medical, Inc. (RCEL) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
28159 Avenue Stanford
Valencia, CA 91355
United States of America (the)
Phone
661 367 9170
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
260
First IPO Date
May 14, 2012
| Name | Title | Pay | Year Born |
| Cary G. Vance | Chief Executive Officer, President & Executive Director | 891,974 | 1966 |
| Nicole Linda Kelsey | Chief Legal & Compliance Officer, Corporate Secretary and Interim SVP of Human Resources | 573,061 | 1967 |
| David O'Toole | Chief Financial Officer | 638,256 | 1959 |
| Katie Bush | Senior Vice President of Scientific & Medical Affairs | 0 | N/A |
| Niraj Doshi | Senior Vice President of Global Operations | 0 | N/A |
| Ben Atkins | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| David Melbye | Senior Vice President of Operations | 0 | N/A |
| Ron Lagerquist | Senior Vice President of Quality Assurance & Regulatory Affairs | 0 | N/A |
| Debbie Garner | Senior Vice President of Global Marketing & Strategy | 0 | N/A |
| Jessica Ekeberg | Director of Investor Relations | 0 | N/A |
| Robin VanDenburgh | Senior Vice President of U.S. Commercial Sales | 0 | N/A |
AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.